These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 35745723)

  • 1. Novel Eye Drop Delivery Systems: Advance on Formulation Design Strategies Targeting Anterior and Posterior Segments of the Eye.
    Wang Y; Wang C
    Pharmaceutics; 2022 May; 14(6):. PubMed ID: 35745723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances and limitations of drug delivery systems formulated as eye drops.
    Jumelle C; Gholizadeh S; Annabi N; Dana R
    J Control Release; 2020 May; 321():1-22. PubMed ID: 32027938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular Drug Delivery - New Strategies for Targeting Anterior and Posterior Segments of the Eye.
    Fangueiro JF; Veiga F; Silva AM; Souto EB
    Curr Pharm Des; 2016; 22(9):1135-46. PubMed ID: 26675225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular drug delivery systems: An overview.
    Patel A; Cholkar K; Agrahari V; Mitra AK
    World J Pharmacol; 2013; 2(2):47-64. PubMed ID: 25590022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclodextrins and topical drug delivery to the anterior and posterior segments of the eye.
    Loftsson T; Stefánsson E
    Int J Pharm; 2017 Oct; 531(2):413-423. PubMed ID: 28391041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aqueous eye drops containing drug/cyclodextrin nanoparticles deliver therapeutic drug concentrations to both anterior and posterior segment.
    Loftsson T; Stefánsson E
    Acta Ophthalmol; 2022 Feb; 100(1):7-25. PubMed ID: 33876553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical ocular drug delivery systems: Innovations for an unmet need.
    Yang Y; Lockwood A
    Exp Eye Res; 2022 May; 218():109006. PubMed ID: 35248559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye.
    Loftsson T; Stefánsson E
    Acta Ophthalmol Scand; 2002 Apr; 80(2):144-50. PubMed ID: 11952479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in Topical Ocular Drug Delivery.
    Yellepeddi VK; Palakurthi S
    J Ocul Pharmacol Ther; 2016 Mar; 32(2):67-82. PubMed ID: 26666398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug delivery to the anterior segment of the eye: A review of current and future treatment strategies.
    Mofidfar M; Abdi B; Ahadian S; Mostafavi E; Desai TA; Abbasi F; Sun Y; Manche EE; Ta CN; Flowers CW
    Int J Pharm; 2021 Sep; 607():120924. PubMed ID: 34324989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioactivation antioxidant and transglycating properties of N-acetylcarnosine autoinduction prodrug of a dipeptide L-carnosine in mucoadhesive drug delivery eye-drop formulation: powerful eye health application technique and therapeutic platform.
    Babizhayev MA
    Drug Test Anal; 2012 Jun; 4(6):468-85. PubMed ID: 21416634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases.
    Babizhayev MA; Kasus-Jacobi A
    Curr Clin Pharmacol; 2009 Jan; 4(1):4-37. PubMed ID: 19149498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular preparations: the formulation approach.
    Kaur IP; Kanwar M
    Drug Dev Ind Pharm; 2002 May; 28(5):473-93. PubMed ID: 12098838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nano-based eye drop: Topical and noninvasive therapy for ocular diseases.
    Wang C; Pang Y
    Adv Drug Deliv Rev; 2023 Mar; 194():114721. PubMed ID: 36773886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ophthalmic drug delivery systems--recent advances.
    Bourlais CL; Acar L; Zia H; Sado PA; Needham T; Leverge R
    Prog Retin Eye Res; 1998 Jan; 17(1):33-58. PubMed ID: 9537794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery.
    Babizhayev MA
    Drug Dev Ind Pharm; 2008 Oct; 34(10):1071-89. PubMed ID: 18777243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydrogel-based ocular drug delivery systems for hydrophobic drugs.
    Torres-Luna C; Fan X; Domszy R; Hu N; Wang NS; Yang A
    Eur J Pharm Sci; 2020 Nov; 154():105503. PubMed ID: 32745587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advance of nanoparticle-based topical drug delivery to the posterior segment of the eye.
    Wang Y; Xu X; Gu Y; Cheng Y; Cao F
    Expert Opin Drug Deliv; 2018 Jul; 15(7):687-701. PubMed ID: 29985660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops.
    Loftsson T; Hreinsdóttir D; Stefánsson E
    J Pharm Pharmacol; 2007 May; 59(5):629-35. PubMed ID: 17524227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New ophthalmic drug delivery systems.
    Castro-Balado A; Mondelo-García C; Zarra-Ferro I; Fernández-Ferreiro A
    Farm Hosp; 2020 Jul; 44(4):149-157. PubMed ID: 32646346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.